Close Menu

More articles about Tools & Technology

The clinical trial matching app, which Roche collaborated on with MolecularMatch, is the latest in a series of features that it will introduce in its tumor board solution.

The researchers said their findings could help classify BRCA1 variants, particularly one whose impact on cancer risk is currently not clear.

An Oregon Health Authority committee issued a draft guidance to not cover NGS testing for solid tumors, which advocacy groups say will limit access to Medicaid beneficiaries.

A phylogenetic analysis that included multiple samples per patient suggests overlapping driver mutations make their way into multiple metastases in each patient.

In urothelial cancer, the presence of a gene signature stemming from stromal cells seemed to interfere with anti-PD-1 drug response in tumors with infiltrating T-cells.

Using archived tumor samples from individuals with glioblastoma, researchers saw methylation variability at progression, along with potential prognostic hints.

The approval includes the use of either tumor tissue or plasma and follows previous approvals with Genentech's Tarceva (erlotinib) and AstraZeneca's Tagrisso (osimertinib).

Researchers screened 2,000 Nigerian women with and without the disease for loss-of-function mutations in 25 known and suspected breast cancer genes.

The platform integrates whole exome and RNA sequencing for downstream RNA-based drug repurposing to treat patients with relapsed multiple myeloma.

Results of the study, published in JAMA, highlight ongoing and future challenges in translating the promise of comprehensive genomics into clinical benefit.

The researchers aim to offer the half-hour diagnostic assay for use during neurosurgery to help clinicians pursue the best treatment for patients with gliomas.  

With panel sequence data from Ambry's clinical lab and a TNBC research consortium, researchers saw risky hereditary variants in BRCA1/2 and other genes.

A Samsung University team found that mutation load measured with the Guardant360 liquid biopsy assay predicted response as well as tissue-based TMB.

New genetic studies are providing insights into the molecular changes that occur as benign moles transition to melanoma and spread to other parts of the body by metastasis.

Researchers analyzed germline mutations in 256 kidney cancer patients and found mutations that would have been missed, including therapeutically relevant ones.

Researchers affiliated with the Pancreatic Cancer Action Network found that treatment based on patient molecular profiles improved progression-free survival.

A new analysis of immune cells in breast carcinomas and matched blood, breast, and lymph tissue uncovered phenotypic expansions in tumor immune cell populations.

On the heels of the WINTHER study, the consortium has planned a new trial called MERCURY, and will launch a blood and tissue repository.

The NCI will launch a lab network to provide researchers with centralized assays for conducting genomic and pharmacodynamic analysis for molecularly targeted drugs.

Two new studies have uncovered expression-defined T cell subsets that seem to coincide with better or worse outcomes in breast cancer or non-small cell lung cancer.

Pages